RBC Capital lowered the firm’s price target on MannKind (MNKD) to $8 from $10 and keeps an Outperform rating on the shares following a transfer of coverage. The stock price reflects an overly pessimistic view of MannKind’s commercial products, especially the Tyvaso DPI royalties, and assigns no value to the pipeline, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNKD:
- MannKind assumed with a Buy at H.C. Wainwright
- MannKind’s Afrezza: A Promising Undervalued Opportunity in Diabetes Treatment
- MannKind’s Growth Potential and Strategic Positioning Amidst Near-Term Uncertainties: A Buy Rating by Faisal Khurshid
- MannKind’s Afrezza: A Significantly Undervalued Investment Opportunity with Promising Clinical Data
- MannKind’s Strategic Growth Potential and Market Positioning: A Buy Recommendation